- State Pharmaceutical Services Divisions
- Retroviral Disease (RVD) Pharmacy Services Protocol: Adult and Paediatric (Third Edition)
- List of Galenical and Extemporaneous (GAEX) Drug Preparations in PhIS System
- List of Appointed Distributors Under Special Conditions of Type A License
- Thalassaemia Medication Therapy Adherence Clinic (TMTAC) Protocol
You are here
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1 | Osimertinib 40mg Tablet | L01XE35-000-T32-01-XXX | A* | The treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy | Second-line therapy, in patients who progressed from first-line EGFR TKI therapy. To be prescribed by oncologists and oncology-trained respiratory physicians | 80 mg once a day until disease progression or unacceptable toxicity, taken with or without food at the same time each day. If dose reduction is necessary, then the dose should be reduced to 40 mg taken once daily. |
| 2 | Osimertinib 80mg Tablet | L01XE35-000-T32-02-XXX | A* | The treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy | Second-line therapy, in patients who progressed from first-line EGFR TKI therapy. To be prescribed by oncologists and oncology-trained respiratory physicians | 80 mg once a day until disease progression or unacceptable toxicity, taken with or without food at the same time each day. If dose reduction is necessary, then the dose should be reduced to 40 mg taken once daily. |